Every‐other‐day palonosetron plus aprepitant for prevention of emesis following induction chemotherapy for acute myeloid leukemia: A randomized, controlled study from the “Rete Ematologica Pugliese”-Reference-Cited by-同舟云学术

Every‐other‐day palonosetron plus aprepitant for prevention of emesis following induction chemotherapy for acute myeloid leukemia: A randomized, controlled study from the “Rete Ematologica Pugliese”

Published:2019-11-14 Issue:1 Volume:9 Page:170-178
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Di Renzo Nicola¹^ORCID,Melillo Lorella²,Porretto Fernando³,Dargenio Michela¹,Pavone Vincenzo⁴,Pastore Domenico⁵,Mazza Patrizio⁶,Mannina Donato⁷,Merenda Anxur⁸,Cascavilla Nicola²,Greco Giuseppina⁴,Matera Rosella¹,Bonizzoni Erminio⁹,Celio Luigi¹⁰^ORCID,Musso Maurizio³

Affiliation:

1. Department of Hematology and Stem Cell Transplant Presidio Ospedaliero Vito Fazzi Lecce Italy

2. Hematology Unit IRCCS Casa Sollievo della Sofferenza San Giovanni Rotondo Italy

3. Hematology Unit Casa di Cura La Maddalena Palermo Italy

4. Hematology Unit Ospedale Cardinale G. Panico Tricase Italy

5. Hematology Unit Ospedale A. Perrino Brindisi Italy

6. Hematology Unit Ospedale S.G. Moscati Taranto Italy

7. Hematology Unit A.O. Ospedali Riuniti Papardo‐Piemonte Messina Italy

8. Hematology Unit Ospeale Civico Palermo Italy

9. Section of Medical Statistics, Biometry and Epidemiology University of Milan Milan Italy

10. Department of Medical Oncology and Hematology Fondazione IRCCS Istituto Nazionale dei Tumori Milan Italy

Publisher

Wiley

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.2628

Reference20 articles.

1. Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting

2. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

3. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients

4. The role of second-generation 5-HT3 receptor antagonists in managing chemotherapy-induced nausea and vomiting in hematological malignancies

5. Prevention of Emesis from Multiple-Day and High-Dose Chemotherapy Regimens

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. 2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting;Supportive Care in Cancer;2023-12-18

2. One-Day Versus Three-Day Dexamethasone with NK1RA for Patients Receiving Carboplatin and Moderate Emetogenic Chemotherapy: A Network Meta-analysis;The Oncologist;2022-04-15